Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Expenses (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Operating Expenses for 7 consecutive years, with $255.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 105.98% year-over-year to $255.3 million, compared with a TTM value of $764.7 million through Dec 2025, up 96.16%, and an annual FY2025 reading of $764.7 million, up 96.16% over the prior year.
  • Operating Expenses was $255.3 million for Q4 2025 at Avidity Biosciences, up from $201.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $255.3 million in Q4 2025 and bottomed at $26.6 million in Q1 2021.
  • Average Operating Expenses over 5 years is $85.8 million, with a median of $60.6 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 253.77% in 2021, then rose 13.35% in 2023.
  • Year by year, Operating Expenses stood at $40.4 million in 2021, then soared by 38.6% to $56.0 million in 2022, then rose by 23.11% to $68.9 million in 2023, then skyrocketed by 79.82% to $124.0 million in 2024, then skyrocketed by 105.98% to $255.3 million in 2025.
  • Business Quant data shows Operating Expenses for RNA at $255.3 million in Q4 2025, $201.3 million in Q3 2025, and $175.0 million in Q2 2025.